Lucas Colombo Godoy

Lucas Colombo Godoy

Auto-generated profile, based on publicly available information

Lucas Colombo Godoy

ICES, Toronto, Ontario, Canada; Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2020 in European Heart Journal
Verified
Journal Article
Closed access
PLPatrick R Lawler
Patrick R Lawler
DBDeepak L Bhatt
Deepak L Bhatt
LGLucas C Godoy
Lucas C Godoy
TLThomas F Lüscher
Thomas F Lüscher
RBRobert O Bonow
Robert O Bonow
PRPaul M Ridker
Paul M Ridker
Systemic vascular inflammation plays multiple maladaptive roles which contribute to the progression and destabilization of atherosclerotic cardiovascular disease (ASCVD). These roles include: (i) driving atheroprogression in the clinically stable phase of disease; (ii) inciting atheroma destabilization and precipitating acute coronary syndromes (ACS); and (iii) responding to cardiomyocyte necrosis in myocardial infarction (MI). Despite an evolving understanding of these biologic processes, successful clinical translation into effective therapies has proven challenging. Realizing the promise of targeting inflammation in the prevention and treatment of ASCVD will likely require more individualized approaches, as the degree of inflammation differs among cardiovascular patients. A large body of evidence has accumulated supporting the use of high-sensitivity C-reactive protein (hsCRP) as a clinical measure of inflammation. Appreciating the mechanistic diversity of ACS triggers and the kinetics of hsCRP in MI may resolve purported inconsistencies from prior observational studies. Future clinical trial designs incorporating hsCRP may hold promise to enable individualized approaches. The aim of this Clinical Review is to summarize the current understanding of how inflammation contributes to ASCVD progression, destabilization, and adverse clinical outcomes. We offer forward-looking perspective on what next steps may enable successful clinical translation into effective therapeutic approaches—enabling targeting the right patients with the right therapy at the right time—on the road to more individualized ASCVD care.

12 June 2023 in JACC
Verified
Journal Article
Closed access
LGLucas C. Godoy
Lucas C. Godoy
MFMichael E. Farkouh
Michael E. Farkouh
PAPeter C. Austin
Peter C. Austin
BSBaiju R. Shah
Baiju R. Shah
FQFeng Qiu
Feng Qiu
DKDennis T. Ko
Dennis T. Ko

7 January 2021 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
CCChristopher Chen
Christopher Chen
GKGurleen Kaur
Gurleen Kaur
PMPuja Mehta
Puja Mehta
DMDoralisa Morrone
Doralisa Morrone
LGLucas C. Godoy
Lucas C. Godoy
MSMandeep S. Sidhu
Mandeep S. Sidhu

1 August 2019 in Canadian Journal of Cardiology
Verified
Journal Article
Closed access
LGLucas C. Godoy
Lucas C. Godoy
PLPatrick R. Lawler
Patrick R. Lawler
MFMichael E. Farkouh
Michael E. Farkouh
BHBronwyn Hersen
Bronwyn Hersen
JNJosé Nicolau
José Nicolau
VRVivek Rao
Vivek Rao

4 March 2022 in Atherosclerosis
Verified
Journal Article
Open access
ALAlexandre Leszek
Alexandre Leszek
LPLauriane Poli
Lauriane Poli
SZStephanie Zbinden
Stephanie Zbinden
LGLucas C. Godoy
Lucas C. Godoy
JRJean-Luc Reny
Jean-Luc Reny
TMThomas A. Mavrakanas
Thomas A. Mavrakanas
Chronic kidney disease (CKD) confers a high risk for poor cardiovascular outcomes. We conducted a systematic review and meta-analysis to estimate the effects of revascularization as the initial management strategy compared with medical therapy among patients with CKD and coronary artery disease. A Medline/PubMed literature research was conducted to identify randomized studies comparing early coronary revascularization with optimal medical therapy or medical therapy alone in patients with CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2 or maintenance dialysis). The primary outcome was myocardial infarction. The secondary outcomes were all-cause mortality or progression to kidney failure. The risk ratio (RR) was estimated using a random-effects model. Eleven randomized trials were included (3422 patients). Revascularization was associated with lower incidence of myocardial infarction compared with medical therapy in patients with CKD: RR 0.71 (95% confidence interval [CI] 0.54-0.94; p=0.02). This result was mainly driven from a significantly lower incidence of myocardial infarction with early revascularization among patients with stable coronary artery disease: RR 0.59; 95% CI 0.37-0.93. A similar incidence of all-cause mortality was observed with both treatment strategies: RR 0.88 (95% CI 0.72-1.08; p=0.22). A trend towards lower incidence of all-cause mortality was observed with revascularization in the subgroup of patients presenting with NSTE-ACS: RR 0.73 (95% CI 0.51-1.04; p=0.08) but not among patients with stable coronary disease. There was no difference in progression to kidney failure between the two strategies. Coronary revascularization may be superior to medical therapy among patients with CKD and coronary disease.

1 December 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
TSThiago Luis Scudeler
Thiago Luis Scudeler
WHWhady A. Hueb
Whady A. Hueb
MFMichael E. Farkouh
Michael E. Farkouh
DMDavid J. Maron
David J. Maron
PSPatricia Coelho de Soárez
Patricia Coelho de Soárez
RFRoberto Kalil Filho
Roberto Kalil Filho